** Jefferies initiates the coverage of Jenoptik JENGn.DE
with "buy", citing that the German optical technology company
will benefit from global trends in digitalization, health and
mobility
** The broker sees a faster EBITDA margin expansion of
360bps to 20% by 2025 driven by the higher margin semi business
and medtec products
** It also expects revenues to grow at a compound annual
growth rate of 12% until 2025 which is broadly in line with
expected photonic market growth
** "After several debt-financed acquisitions, we expect
balance sheet metrics to improve going forward", Jefferies notes
** It adds that the interplay of positive free cash flow
generation including an improving working capital, potential
further divestments and a flexible dividend strategy, will
provide firepower in a changing M&A environment where subdued
multiples offer new opportunities
** Jenoptik shares now up 5.2% and the stock is among the
best performers on Germany's small-cap index .SDAXI
** Out of 14 analysts that cover Jenoptik AG, 11 rate the
stock "strong buy" or "buy", and three rate "hold"
($1 = 1.0131 euros)
(Reporting by Ozan Ergenay)
((ozan.ergenay@thomsonreuters.com))